Urothelial carcinoma treatment: the future

7 Views

01/01/24

Arlene Siefker-Radtke, MD, of the MD Anderson Cancer Center, Houston, TX, reviews treatment options for bladder cancer. She highlights how MVAC is still used today, with clinical trials failing to identify agents with improved activity over this therapy. New immune checkpoint inhibitors are producing durable response, but only a small fraction of patients respond to these drugs. Dr Siefker-Radtke eloquently provides her insight into the view that bladder cancer is comprised of multiple tumor types and predicts the future of urothelial carcinoma therapy. This interview was recorded at the American Society of Oncology (ASCO) 2018 Annual Meeting, held in Chicago, IL.